PHARMACOKINETICS, PHARMACODYNAMICS, AND TOLERABILITY OF VERINURAD (RDEA3170), A SELECTIVE URIC ACID REABSORPTION INHIBITOR, IN HEALTHY JAPANESE MALE SUBJECTS

被引：0
|
作者：
Gillen, M. [1 ]
Miner, J. N. [2 ]
Valdez, S. [2 ]
机构：
[1] AstraZeneca, Gaithersburg, MD USA
[2] Ardea Biosci Inc, San Diego, CA USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2017年 / 76卷
关键词：
D O I：
10.1136/annrheumdis-2017-eular.5200
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
AB0887
引用
收藏
页码：1366 / 1366
页数：1
相关论文
共 50 条
  • [31] Tolerability, pharmacokinetics and pharmacodynamics of TA-8995, a selective cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects
    Ford, John
    Lawson, Matt
    Fowler, David
    Maruyama, Nobuko
    Mito, Seiji
    Tomiyasu, Koichi
    Kinoshita, Shuji
    Suzuki, Chisa
    Kawaguchi, Atsuhiro
    Round, Patrick
    Boyce, Malcolm
    Warrington, Steve
    Weber, Werner
    van Deventer, Sander
    Kastelein, John J. P.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2014, 78 (03) : 498 - 508
  • [32] Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Intravenous Dose of Miridesap in Healthy Japanese Subjects
    Ino, Hiroko
    Doi, Yohei
    Liefaard, Lia
    Cookson, Louise
    Chen, Chao
    Itoh, Hiroshi
    Igarashi, Harue
    Nakano, Atsushi
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2019, 8 (05): : 612 - 618
  • [33] Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Rising TAK-438 (Vonoprazan) Doses in Healthy Male Japanese/non-Japanese Subjects
    Sakurai, Yuuichi
    Nishimura, Akira
    Kennedy, Gale
    Hibberd, Mark
    Jenkins, Richard
    Okamoto, Hiroyuki
    Yoneyama, Tomoki
    Jenkins, Helen
    Ashida, Kiyoshi
    Irie, Shin
    Taeubel, Joerg
    CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY, 2015, 6
  • [34] PHARMACOKINETICS, PHARMACODYNAMICS, SAFETY AND TOLERABILITY OF A NOVEL FACTOR XIA INHIBITOR ADMINISTERED AS IV INFUSION IN NON-JAPANESE AND JAPANESE HEALTHY SUBJECTS.
    Perera, V.
    Frost, C. E.
    Yones, C. L.
    Wang, Z.
    Dorizio, S.
    Russo, C.
    Chen, W.
    Ueno, T.
    Akimoto, M.
    Cirincione, B.
    Xu, X.
    Seiffert, D. A.
    Desouza, M. M.
    Mugnier, P.
    LaCreta, F.
    Frost, R. J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 101 (S1) : S42 - S42
  • [35] Pharmacokinetics, pharmacodynamics and tolerability of oral cromolyn sodium/SNAC capsules in healthy and allergic male subjects
    Kremer, IB
    Abbas, R
    Arbit, E
    Van Lier, JJ
    Sollie, FAE
    Willemsen, MJJF
    Oosterhuis, B
    Van Vliet, AA
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 56 (04) : 467 - 468
  • [36] Pharmacokinetics, pharmacodynamics, and tolerability of LC350189, a novel xanthine oxidase inhibitor, in healthy subjects
    Yoon, Seonghae
    Shin, Donghoon
    Lee, Howard
    Jang, In-Jin
    Yu, Kyung-Sang
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2015, 9 : 5033 - 5049
  • [37] PHARMACOKINETICS, PHARMACODYNAMICS AND TOLERABILITY OF LC350189, A NOVEL XANTHINE OXIDASE INHIBITOR, IN HEALTHY SUBJECTS
    Yoon, S.
    Moon, S.
    Jang, K.
    Jang, I.
    Lim, K.
    Yu, K.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2014, 95 : S94 - S94
  • [38] Pharmacokinetics, Pharmacodynamics and Tolerability of Opicapone, a Novel Catechol-O-Methyltransferase Inhibitor, in Healthy Subjects
    Almeida, Luis
    Rocha, Jose Francisco
    Falca, Amilcar
    Nuno Palma, P.
    Loureiro, Ana I.
    Pinto, Roberto
    Bonifacio, Maria Joao
    Wright, Lyndon C.
    Nunes, Teresa
    Soares-da-Silva, Patricio
    CLINICAL PHARMACOKINETICS, 2013, 52 (02) : 139 - 151
  • [39] The effect for hyperuricemia inpatient of uric acid overproduction type or in combination with topiroxostat on the pharmacokinetics, pharmacodynamics and safety of dotinurad, a selective urate reabsorption inhibitor
    Okui, Daisuke
    Sasaki, Tomomitsu
    Fushimi, Masahiko
    Ohashi, Tetsuo
    CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2020, 24 (SUPPL 1) : 92 - 102
  • [40] The effect for hyperuricemia inpatient of uric acid overproduction type or in combination with topiroxostat on the pharmacokinetics, pharmacodynamics and safety of dotinurad, a selective urate reabsorption inhibitor
    Daisuke Okui
    Tomomitsu Sasaki
    Masahiko Fushimi
    Tetsuo Ohashi
    Clinical and Experimental Nephrology, 2020, 24 : 92 - 102
12345